Market Capitalization (Millions $) |
222 |
Shares
Outstanding (Millions) |
411 |
Employees |
1,650 |
Revenues (TTM) (Millions $) |
279 |
Net Income (TTM) (Millions $) |
-39 |
Cash Flow (TTM) (Millions $) |
-114 |
Capital Exp. (TTM) (Millions $) |
1 |
Amarin Corp Plcuk
Amarin Corporation plc is a biopharmaceutical company that develops and commercializes therapeutic products for the treatment of cardiovascular diseases. The company is based in Dublin, Ireland and its main trading venue is the NASDAQ stock exchange in New York.
Amarin has developed a proprietary technology platform called the VASCEPAe (icosapent ethyl) drug product, which is a prescription medicine that is FDA-approved for the treatment of adult patients with severe hypertriglyceridemia (triglyceride levels above 500 mg/dL). Hypertriglyceridemia is a condition where the levels of triglycerides in the blood are elevated, and this can be a risk factor for the development of cardiovascular diseases like heart attacks and strokes.
VASCEPAe is a highly purified omega-3 fatty acid product that has been shown in clinical trials to reduce triglyceride levels in patients with hypertriglyceridemia. It is also believed that VASCEPAe has other beneficial effects on the cardiovascular system, including reductions in inflammation and improvements in lipid profiles.
Amarin is also conducting research into the use of its omega-3 fatty acid technology for the treatment of other cardiovascular and metabolic diseases. The company has a pipeline of clinical development programs that are focused on a range of indications, including cardiovascular risk reduction in patients with statin therapy, chronic kidney disease, and diabetes mellitus.
Since its inception in 1993, Amarin has raised over $1 billion in funding through a combination of public offerings, private placements, and grants. The company has also entered into partnerships with several pharmaceutical companies, including Kowa Pharmaceuticals America, which is responsible for the commercialization of VASCEPAe in the US.
Despite facing competition from other omega-3 fatty acid products on the market, Amarin has been able to maintain a strong position in the hypertriglyceridemia treatment market due to the unique properties of VASCEPAe. The company's strong financial position and ongoing commitment to research and development make it an attractive investment opportunity for investors who are interested in the biopharmaceutical sector.
Company Address: One Central Plaza Dublin 2
Company Phone Number: 6699 020 Stock Exchange / Ticker: NASDAQ AMRN
|